SKOKIE, Ill. & RAVENSBURG, Germany—Vetter, a globally operating contract development and manufacturing organization (CDMO), announced in mid-April that a significant level of expansion activities are nearing completion at its U.S. clinical manufacturing facility located at the Illinois Science & Technology Park in suburban Chicago.
The ongoing growth of the facility will help satisfy existing and ever-increasing future customer requirements, as well as meet the complex needs of newer drug molecules like peptides or antibodies, many of which need refrigeration or freezing.
New offices with 45 work stations, conference rooms and an archive room are also included. To support the increase in customer projects, a permanent second work shift will be added in visual inspection over the next months. A second shift in quality oversight is also planned.
“This variety of activities is a further proof point of Vetter’s consistent strategic approach to stay ahead of the market by focusing on the important service needs of our customers during their drug development journey: promptness, flexibility, high yield of their valuable API, and, of course, high quality,” explained Dr. Claus Feussner, senior vice president of Vetter Development Service.
Since beginning full operations in late 2011, Vetter’s U.S.-based early-stage development site has been expanding to help meet growing customer demands. As recently as 2016, the site expanded its storage capacity by 150 percent to 3,700 sq. ft. With the new additions, most of which were expected to be completed by April, the site will increase its storage space by an additional 3,100 sq. ft.
“When completed, the facility will have more than double the overall storage space we have currently available. This extensive expansion of freezer and refrigeration storage space represents the ongoing evolution in our Chicago business,” summarized Dr. Susanne Lemaine, vice president of Vetter Development Service Chicago.
